Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07359859) titled 'A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant' on Jan. 21.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Hematologic Malignancies
Intervention:
Drug: Cyclophosphamide
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Ruxolitinib
Drug: Tacrolimus
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: January ...